Dehydroepiandrosterone-sulfate inhibits nuclear factor-κB-dependent transcription in hepatocytes, possibly through antioxidant effect

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 7, 2004, Pages 3449-3454

  Iwasaki, Yasumasa ^a,b   Asai, Masato ^a   Yoshida, Masanori ^a   Nigawara, Takeshi ^a   Kambayashi, Machiko ^a   Nakashima, Nobuo ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYTOKINE; ESTRADIOL; GLUCOCORTICOID; HYDROXYL RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE; TESTOSTERONE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; CELL STRAIN; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FUSION GENE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; ROUS SARCOMA ONCOVIRUS;

ANTIOXIDANTS; CELL LINE, TUMOR; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DEXAMETHASONE; HEPATOCYTES; HUMANS; INTERLEUKIN-1; NF-KAPPA B; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

ONCOVIRINAE; ROUS SARCOMA VIRUS;

EID: 3242676731     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031441     Document Type: Article

References (37)

1. Baulieu E-E 1996 Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 81:3147-3151
2. Yen SS 2001 Dehydroepiandrosterone sulfate and longevity: new clues for an old friend. Proc Natl Acad Sci USA 98:8167-8169
3. Labrie F, Luu-The V, Labrie C, Simard J 2001 DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22:185-212
4. Nawata H, Yanase T, Goto K, Okabe T, Ashida K 2002 Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Ageing Dev 123:1101-1106
5. Svec F, Porter JR 1998 The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218:174-191
6. i2/3. J Biol Chem 277:21379-21388
7. Aragno M, Mastrocola R, Brignaidello E, Catalano M, Robino G, Manti R, Parola M, Danni O, Boccuzzi G 2002 Dehydroepiandrosterone modulates nuclear factor-κB activation in hippocampus of diabetic rats. Endocrinology 143:3250-3258
8. Cha-Molstad H, Agrawal A, Zhang D, Samols D, Kushner I 2000 The Rel family member p50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 165:4592-4597
9. Bing Z, Huang JH, Liao WS 2000 NF-κB interacts with serum amyloid A3 enhancer factor to synergistically activate mouse serum amyloid A3 gene transcription. J Biol Chem 275:31616-31623
10. Ruan QR, Zhang WJ, Hufnagl P, Kaun C, Binder BR, Wojta J 2001 Anisodamine counteracts lipopolysaccharide-induced tissue factor and plasminogen activator inhibitor-1 expression in human endothelial cells: contribution of the NF-κB pathway. J Vasc Res 38:13-19
11. Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D 2000 The Factor VIII acute phase response requires the participation of NFκB and C/EBP. Thromb Haemost 84:216-222
12. Aoki Y, Iwasaki Y, Kalahira M, Oiso Y, Saito H 1997 Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. I: Effects of the common secretagogues. Endocrinology 138:1923-1929
13. Lavrovsky Y, Chatterjee B, Clark RA, Roy AK 2000 Role of redox-regulated transcription factors in inflammation, aging and age-related diseases. Exp Gerontol 35:521-532
14. Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ, Shah AM 2002 Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-α. Circ Res 90:143-150
15. van Vollenhoven RF 2002 Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 3:23-31
16. Straub RH, Scholmerich J, Zietz B 2000 Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases-substitutes of adrenal and sex hormones. Z Rheumatol 59(Suppl 2):II/108-118
17. Yamaji T, Ibayashi H1969 Plasma dehydroepiandrosterone sulfate in normal and pathological conditions. J Clin Endocrinol Metab 29:273-278
18. Barrett-Connor E, Khaw KT, Yen SS 1986 A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519-1524
19. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F 2000 Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 97:4279-4284
20. McKay LI, Cidlowski JA 1999 Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev 20:435-459
21. Gabay C, Kushner I 1999 Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454
22. Lagrand WK, Visser CA, Hermens WT, Niessen HWM, Verheugt FWA, Wolbink G-J, Hack CE 1999 C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100:96-102
23. Grimble RF 2002 Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5:551-559
24. Collins T, Cybulsky MI 2001 NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107:255-264
25. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP 1999 The role of oxidative stress and NF-κB activation in late diabetic complications. Biofactors 10:157-167
26. De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G 2000 Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 97:3919-3924
27. Sen CK, Packer I 1996 Antioxidant and redox regulation of gene transcription. FASEB J 10:709-720
28. Mohan PF, Jacobson MS 1993 Inhibition of macrophage superoxide generation by dehydroepiandrosterone. Am J Med Sci 306:10-15
29. Tamagno E, Aragno M, Boccuzzi G, Gallo M, Parola S, Fubini B, Poli G, Danni O 1998 Oxygen free radical scavenger properties of dehydroepiandrosterone. Cell Biochem Funct 16:57-63
30. van Rensburg SJ, Daniels WM, van Zyl JM, Taljaard JJ 2000 A comparative study of the effects of cholesterol, β-sitosterol, β-sitostero glucoside, dehydroepiandrosterone sulphate and melatonin on in vitro lipid peroxidation. Metab Brain Dis 15:257-265
31. Barger SW, Chavis JA, Drew PD 2000 Dehydroepiandrosterone inhibits microglial nitric oxide production in a stimulus-specific manner. J Neurosci Res 62:503-509
32. Peters JM, Zhou YC, Ram PA, Lee SS, Gonzalez FJ, Waxman DJ 1996 Peroxisome proliferator-activated receptor a required for gene induction by dehydroepiandrosterone-3 β-sulfate. Mol Pharmacol 50:67-74
33. Poynter ME, Daynes RA 1998 Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841
34. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA 2002 Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 87:176-181
35. Webb SJ, McPherson JR, Pahan K, Koka S 2002 Regulation of TNF-α-induced IL-6 production in MG-63 human osteoblast-like cells. J Dent Res 81:17-22
36. Ross R 1999 Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126
37. Libby P, Ridker PM, Maseri A 2002 Inflammation and atherosclerosis. Circulation 105:1135-1143